The FXR-FGF-19 axis has long been recognised as a therapeutic target, e.g., through pharmacological activation with FXR agonists, also in patients with IBD, particularly those with active inflammation and the concomitant disruption of bile acid metabolism (e.g., after ileocecal resection in patients with CD) [32,33]. Here, NR1H4 is linked to inflammatory bowel disease.